- Abstract Number: 2176
A Novel Composite Score Reflecting Disease Activity Predicts Future Knee Replacements: Data from the Osteoarthritis Initiative
- Abstract Number: 755
A Novel Diagnostic Algorithm for Polymyalgia Rheumatica Using Three Musculoskeletal Sites on Whole Body PET/CT
- Abstract Number: 959
A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting
- Abstract Number: 641
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
- Abstract Number: 1536
A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
- Abstract Number: 424
A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index
- Abstract Number: 6
A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts
- Abstract Number: 982
A Novel Role for Nod2 in Controlling Autoantibody Production and Arthritis in SKG Mice
- Abstract Number: 55
A Novel Subclass of Intravascular Non-classical, Tissue Resident Synovial Monocyte Is Critical for Rheumatoid Arthritis Pathogenesis
- Abstract Number: 828
A Path Model Analysis of the Cognitive Determinants of Physical Activity Among Patients with Fibromyalgia (FM)
- Abstract Number: 943
A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
- Abstract Number: 2760
A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
- Abstract Number: 532
A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics
- Abstract Number: 2559
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
- Abstract Number: 2417
A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 198
- Next Page »